Astellas’ Prograf “Approvable” For Use In Combination With Roche’s CellCept
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will meet with FDA to get combination therapy for prevention of kidney transplant rejection approved.
You may also be interested in...
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1